Abstract
The current study is carried out using in silico approach to find some potent drug molecule against Huntington's disease. Mutant Huntingtin protein (HTT), HTT-interacting protein 1 (HIP-1) were used as the target protein for drug designing. Swiss PDB Viewer (SPDBW) was used for active site determination. Ligands were prepared through Molinspiration Cheminformatics following Lipinski rule of five (RO5). Bioinformatics software Molegro virtual Docker (MVD) and HEX were used for docking between the ligands and target proteins. Eleven ligands were prepared and compared with drugs based on MolDock score and hydrogen bond score. Four ligands - named [1-benzyl-6bromo-8-((4-ethyl-2hydroxy-2H- pyran-6y1)methyl)-4-hydroxy-7,8dihydro-1,8-naphthydrin-2(1H)-one], [4-((3-amino- 5bromocyclohexyl)methoxy)-5-butyl-6hydroxydechydronaphthalene-2-carboxylic acid], [3- amino-2-chloro-13-(2-hydroxybutyl)-5-nitro-2,3-dihydro-7H-benzo[c][1,4]dioxino[2,3-h] xanthen-7-one] and [3-(3'-bromo-[1,1'-bi(cyclohexan)]-3-y1)-6-(4-methoxy-4-oxobutanamido)hexanoic acid] respectively with most appropriate values as -731.31 for MolDock score and -33.51 for H-Bond score are found to be potential drug candidate for Huntington's Disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Computational Biology and Drug Design
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
